LexDanaLexDanabeta
Inventor

QINGMING ZHU

Inventor
US

Overview

5→
Patents
2023–2025
Patent span
Human necessities
Primary field (CPC A)

Patents· 5 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07DHeterocyclic compounds24%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium10%
C07KPeptides10%
Y02ATechnologies for adaptation to climate change10%
PatentTitleYear
12,202,842MCL1 inhibitors202512,054,490Diacylglycerol kinase modulating compounds202411,976,072Diacylglycerol kinase modulating compounds202411,845,723Diacylglycerol kinase modulating compounds202311,667,652MCL1 inhibitors2023

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2023–2025Patents assigned to GILEAD SCIENCES INC (5)· patent assignee history
2023–2024Patents assigned to CARNA BIOSCIENCES INC (2)· patent assignee history
2023–2025Based in US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GILEAD SCIENCES INC52023–2025
CARNA BIOSCIENCES INC22023–2024
Locations
LocationPatentsSpan
US52023–2025